Skip to main content
. 2016 Aug 23;24(9):1634–1643. doi: 10.1038/mt.2016.141

Figure 3.

Figure 3

Cytotoxic activity of patient PBMC over course of 4G7SDIE treatment against autologous blasts. (a) Primary B-lineage acute lymphoblastic leukemia blasts from patient #2 were incubated with autologous PBMC of the patient (PBMC: target ratio 20:1) with or without 1 µg/ml 4G7SDIE and with autologous serum. PBMC were taken prior to antibody infusion, autologous serum was taken 1 hour after antibody infusion. Specific lysis was measured in DELFIA 2 h-EuTDA cytotoxicity assays. 4G7SDIE infusions are indicated by arrows. 1 µg/ml 4G7SDIE significantly increased cytolysis, n = 6, P = 0.02 (one-way ANOVA). (b) B cell counts (CD19+ or CD20+) and NK cell counts (CD56+CD16+) in whole blood were determined over course of treatment by routine flow cytometry.